

Please provide, for the **total population**, OS, TTP, ORR and CBR outcome data for patients who received previous endocrine therapy with AO(s) only, AI(s) only and both an AO and AI (i.e. they received these treatments for either adjuvant therapy **or** advanced disease)

Please enter the data for █ in each relevant cell

	fulvestrant 500 mg (N=362)	fulvestrant 250 mg (N=374)	Comparison between groups (fulvestrant 500 mg/fulvestrant 250 mg)		
OS	K-M median in months		Hazard ratio	95% CI	p-value
All Patients	25.1	22.8	0.84	0.69, 1.03	0.091
█	█	█	█	█	█
█	█	█	█	█	█
█	█	█	█	█	█
TTP	K-M median in months		Hazard ratio	95% CI	P-value
All Patients	6.5	5.5	0.80	0.68, 0.94	0.006
█	█	█	█	█	█
█	█	█	█	█	█
█	█	█	█	█	█
ORR	% of patients with OR		Absolute difference in %	95% CI	
All Patients	13.8	14.6	-0.8	-5.8, 6.3	
█	█	█	█	█	
█	█	█	█	█	
█	█	█	█	█	
CBR	% of patients with CB		Absolute difference in %	95% CI	
All Patients	45.6	39.6	6.0	-1.1, 13.3	
█	█	█	█	█	
█	█	█	█	█	
█	█	█	█	█	
Number of prior endocrine therapies	no. (%) of patients				
0	█	█			
1	█	█			
2	█	█			
≥3	█	█			

Please provide, **for patients treated with adjuvant endocrine therapy**, the OS, TTP, ORR and CBR outcome data for patients who received previous endocrine therapy with AO(s) only, AI(s) only and both an AO and AI

Please enter the data for █ in each relevant cell

	fulvestrant 500 mg (N=█)	fulvestrant 250 mg (N=█)	Comparison between groups (fulvestrant 500 mg/fulvestrant 250 mg)		
OS	K-M median in months		Hazard ratio	95% CI	p-value
All Patients treated with adjuvant therapy	█	█	█	█	█
█	█	█	█	█	█
█	█	█	█	█	█
█	█	█	█	█	█
TTP	K-M median in months		Hazard ratio	95% CI	P-value
All Patients treated with adjuvant therapy	█	█	█	█	█
█	█	█	█	█	█
█	█	█	█	█	█
█	█	█	█	█	█
ORR	% of patients with OR		Absolute difference in %	95% CI	
All Patients treated with adjuvant therapy	█	█	█	█	
█	█	█	█	█	
█	█	█	█	█	
█	█	█	█	█	
CBR	% of patients with CB		Absolute difference in %	95% CI	
All Patients treated with adjuvant therapy	█	█	█	█	
█	█	█	█	█	
█	█	█	█	█	
█	█	█	█	█	
Number of prior endocrine therapies	no. (%) of patients				
0	█	█			
1	█	█			
2	█	█			
≥3	█	█			

Please provide, for patients **previously treated for advanced disease**, the OS, TTP, ORR and CBR outcome data for patients who received previous endocrine therapy with AO(s) only, AI(s) only and both an AO and AI

Please enter the data for █ in each relevant cell

	fulvestrant 500 mg (N=█)	fulvestrant 250 mg (N=█)	Comparison between groups (fulvestrant 500 mg/fulvestrant 250 mg)		
OS	K-M median in months		Hazard ratio	95% CI	p-value
All Patients treated for advanced disease	█	█	█	█	█
█	█	█	█	█	█
█	█	█	█	█	█
█	█	█	█	█	█
TTP	K-M median in months		Hazard ratio	95% CI	P-value
All Patients treated for advanced disease	█	█	█	█	█
█	█	█	█	█	█
█	█	█	█	█	█
█	█	█	█	█	█
ORR	% of patients with OR		Absolute difference in %	95% CI	
All Patients treated for advanced disease	█	█	█	█	
█	█	█	█	█	
█	█	█	█	█	
█	█	█	█	█	
CBR	% of patients with CB		Absolute difference in %	95% CI	
All Patients treated for advanced disease	█	█	█	█	
█	█	█	█	█	
█	█	█	█	█	
█	█	█	█	█	
Number of prior endocrine therapies	no. (%) of patients				
0	█	█			
1	█	█			
2	█	█			
≥3	█	█			